Jean-Pierre Rosat, MoT Class 1999, Founder & CEO
Aleva Neurotherapeutics has developed proprietary neurostimulation technologies that enable significantly better therapies for neurological diseases.
Deep Brain Stimulation (DBS) therapy, used in indications including Parkinsonʼs Disease, is an existing market growing at over 15% annually and is Alevaʼs first target market.
With Alevaʼs microDBS products, neurosurgeons and neurologists will see reduced surgical and follow-up times, patients will benefit from a decrease in debilitating side effects, and payers will see a
substantial reduction in cost-of-care.